Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs

BACKGROUND: Genetic therapies are a promising treatment for children born with spinal muscular atrophy (SMA); however, their high price tags can evoke coverage restrictions. OBJECTIVE: To assess variation in coverage guidelines across fee-for-service state Medicaid programs for 2 novel genetic thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballreich, Jeromie, Ezebilo, Ijeamaka, Khalifa, Banda Abdallah, Choe, Joshua, Anderson, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372955/
https://www.ncbi.nlm.nih.gov/pubmed/34949120
http://dx.doi.org/10.18553/jmcp.2022.28.1.39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372955/
https://www.ncbi.nlm.nih.gov/pubmed/34949120
http://dx.doi.org/10.18553/jmcp.2022.28.1.39

Ejemplares similares